These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 31219556)

  • 1. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
    Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
    Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic remodeling and calcium handling abnormality in induced pluripotent stem cell-derived cardiomyocytes in dilated phase of hypertrophic cardiomyopathy with MYBPC3 frameshift mutation.
    Mori H; Xu D; Shimoda Y; Yuan Z; Murakata Y; Xi B; Sato K; Yamamoto M; Tajiri K; Ishizu T; Ieda M; Murakoshi N
    Sci Rep; 2024 Jul; 14(1):15422. PubMed ID: 38965264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
    Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
    Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
    Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.
    Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC
    J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
    Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
    J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation.
    Dutton LC; Dudhia J; Guest DJ; Connolly DJ
    PLoS One; 2024; 19(10):e0311761. PubMed ID: 39388496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells.
    Pavlova SV; Shulgina AE; Zakian SM; Dementyeva EV
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
    Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
    J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
    Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
    Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
    Sakai T; Naito AT; Kuramoto Y; Ito M; Okada K; Higo T; Nakagawa A; Shibamoto M; Yamaguchi T; Sumida T; Nomura S; Umezawa A; Miyagawa S; Sawa Y; Morita H; Lee JK; Shiojima I; Sakata Y; Komuro I
    Int Heart J; 2018 Sep; 59(5):1096-1105. PubMed ID: 30101858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
    Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
    J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.